CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Osteolytic bone disease is a hallmark of multiple myeloma (MM). A significant fraction (~20%) of MM patients do not develop osteolytic lesions (OLs). The molecular basis for the absence of bone disease in MM is not understood. We combined PET-CT and gene expression profiling (GEP) of purified BM CD1...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
American Society for Clinical Investigation
2022-09-01
|
| Rangatū: | The Journal of Clinical Investigation |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1172/JCI159527 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
